HK1217291A1 - 用於治療 、肝性脂肪變性及其後遺症的方法和組合物 - Google Patents
用於治療 、肝性脂肪變性及其後遺症的方法和組合物Info
- Publication number
- HK1217291A1 HK1217291A1 HK16105268.6A HK16105268A HK1217291A1 HK 1217291 A1 HK1217291 A1 HK 1217291A1 HK 16105268 A HK16105268 A HK 16105268A HK 1217291 A1 HK1217291 A1 HK 1217291A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nafld
- sequelae
- compositions
- methods
- hepatic steatosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IL2013/050007 WO2013102899A1 (en) | 2012-01-03 | 2013-01-03 | Methods and compositions for treating diabetes |
US201361763996P | 2013-02-13 | 2013-02-13 | |
PCT/IL2014/050007 WO2014106846A2 (en) | 2013-01-03 | 2014-01-02 | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1217291A1 true HK1217291A1 (zh) | 2017-01-06 |
Family
ID=51062529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16105268.6A HK1217291A1 (zh) | 2013-01-03 | 2016-05-09 | 用於治療 、肝性脂肪變性及其後遺症的方法和組合物 |
Country Status (6)
Country | Link |
---|---|
US (4) | US20150335715A1 (zh) |
EP (2) | EP4215205A1 (zh) |
JP (4) | JP2016505613A (zh) |
CN (2) | CN104902921A (zh) |
HK (1) | HK1217291A1 (zh) |
WO (1) | WO2014106846A2 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5222727B2 (ja) * | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
BRPI0907077A2 (pt) | 2008-03-26 | 2016-07-26 | Oramed Ltd | métodos e composições para administração oral de proteínas |
US20110046053A1 (en) | 2008-05-05 | 2011-02-24 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
ES2644962T3 (es) | 2012-01-03 | 2017-12-01 | Oramed Ltd. | Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes |
CN104244969A (zh) | 2012-02-01 | 2014-12-24 | 奥拉姆德有限公司 | 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法 |
JP2016505613A (ja) * | 2013-01-03 | 2016-02-25 | オラムド エルティーディー. | Nafld、脂肪肝、および、その後遺症を処置するための方法および組成物 |
TR201809418T4 (tr) | 2013-03-13 | 2018-07-23 | Takeda Pharmaceuticals Co | Guanidinobenzoik asit ester bileşiği. |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
WO2016046822A1 (en) * | 2014-09-22 | 2016-03-31 | Hadasit Medical Research Services And Development Ltd. | Alpha-1 anti-trypsin for treating liver diseases |
EP3518918A4 (en) * | 2016-09-28 | 2020-04-22 | Eiger Biopharmaceuticals, Inc. | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS |
CN109806386A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Fxr激动剂与glp-1类似物的药物组合物和用途 |
EP3801595A1 (en) * | 2018-06-11 | 2021-04-14 | Oramed Ltd. | Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof |
WO2021142733A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
CN116251192A (zh) * | 2020-01-16 | 2023-06-13 | 上海仁会生物制药股份有限公司 | Glp-1给药方案 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
JPS6350793A (ja) | 1986-08-20 | 1988-03-03 | 株式会社東芝 | 高速増殖炉の崩壊熱除去システム |
US5034415A (en) | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
ATE94404T1 (de) | 1988-07-21 | 1993-10-15 | Hoffmann La Roche | Insulinzubereitung. |
JPH02250823A (ja) | 1989-03-24 | 1990-10-08 | Tsumura & Co | マイクロカプセル剤およびその製造方法 |
GB9007052D0 (en) | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
WO1994011516A1 (en) * | 1992-11-17 | 1994-05-26 | E.I. Du Pont De Nemours And Company | Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants |
US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
IL114673A (en) | 1995-07-19 | 2000-12-06 | Hadasit Med Res Service | Pharmaceutical compositions containing protein for oral administration |
JPH09208485A (ja) | 1996-01-31 | 1997-08-12 | Teijin Ltd | ペプチド・蛋白質性薬物の水難溶性組成物 |
DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
JPH10330287A (ja) | 1997-03-31 | 1998-12-15 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤 |
JP2000128805A (ja) | 1998-10-27 | 2000-05-09 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤 |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
CN1245216C (zh) * | 1999-10-04 | 2006-03-15 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
JP2001240558A (ja) | 2000-02-29 | 2001-09-04 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。 |
US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
KR20010069322A (ko) | 2001-03-08 | 2001-07-25 | 서종수 | 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법 |
KR20010069433A (ko) | 2001-03-22 | 2001-07-25 | 김윤완 | 노루궁뎅이버섯을 이용한 건강 보조 식품 |
CN1160122C (zh) | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
WO2003007976A1 (en) | 2001-07-18 | 2003-01-30 | Solae, Llc | High protein, bowman-birk inhibitor concentrate and process for its manufacture |
US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US20050143303A1 (en) | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
JP2007532629A (ja) | 2004-04-15 | 2007-11-15 | キアスマ, インコーポレイテッド | 生物学的障壁を横切る透過を促進し得る組成物 |
UA91512C2 (ru) | 2004-07-19 | 2010-08-10 | Биокон Лимитед | Коньюгати олигомеров инсулина, их композиция (варианты) и применение |
EP1789075A4 (en) | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
BRPI0518241A (pt) * | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
WO2007022518A2 (en) * | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
JP5222727B2 (ja) | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
US20070086972A1 (en) | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
US20070077283A1 (en) | 2005-09-30 | 2007-04-05 | Nastech Pharmaceutical Company Inc. | Method of enhancing transmucosal delivery of therapeutic compounds |
CN101095942B (zh) | 2006-06-30 | 2011-11-16 | 北京民海生物科技有限公司 | 一种包含稳定剂的Exendin-4注射剂药物配方 |
RU2509071C2 (ru) | 2006-11-01 | 2014-03-10 | Пронова Биофарма Норге Ас | Новые липидные соединения |
CA2682068C (en) | 2007-03-28 | 2017-11-28 | Aker Biomarine Asa | Bioeffective krill oil compositions |
BRPI0907077A2 (pt) * | 2008-03-26 | 2016-07-26 | Oramed Ltd | métodos e composições para administração oral de proteínas |
US20110046053A1 (en) | 2008-05-05 | 2011-02-24 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
US20110092592A1 (en) * | 2008-06-13 | 2011-04-21 | Takashi Yano | Diagnosis and treatment of hepatic disorder |
US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
WO2009154230A1 (ja) | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防/改善・治療薬 |
DK2300035T3 (en) * | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
US20110305768A1 (en) | 2008-07-01 | 2011-12-15 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
JP5740689B2 (ja) | 2008-08-18 | 2015-06-24 | エンテラ バイオ エルティーディー. | タンパク質の経口投与用の方法および組成物 |
UY32177A (es) | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
EP2427415B1 (en) | 2009-05-08 | 2019-03-20 | Basf As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
EP2488180A4 (en) | 2009-10-12 | 2013-03-27 | Ipca Lab Ltd | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS |
CA2785599A1 (en) | 2009-12-30 | 2011-07-07 | Solae, Llc | Purified bowman-birk protease inhibitor proteins isolated from a soy processing stream |
US20130273154A1 (en) | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
BR112012032579B1 (pt) * | 2010-06-24 | 2021-05-11 | Boehringer Ingelheim International Gmbh | uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração |
TWI541030B (zh) * | 2010-07-06 | 2016-07-11 | 健生藥品公司 | 用於糖尿病協同治療之調配物 |
ES2659763T3 (es) * | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
CN102219850A (zh) * | 2011-05-03 | 2011-10-19 | 上海格尼生物技术有限公司 | 新的长效glp-1化合物 |
JP2014520159A (ja) * | 2011-06-24 | 2014-08-21 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | Glp−1受容体アゴニストの徐放性製剤による糖尿病の治療方法 |
CN103717789A (zh) | 2011-07-15 | 2014-04-09 | 明通企业股份有限公司 | 填充式工件表面饰化方法 |
UY34347A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
ES2644962T3 (es) * | 2012-01-03 | 2017-12-01 | Oramed Ltd. | Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes |
CN104244969A (zh) * | 2012-02-01 | 2014-12-24 | 奥拉姆德有限公司 | 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法 |
EP2844269A4 (en) * | 2012-03-28 | 2016-01-06 | Amylin Pharmaceuticals Llc | TRANSMUCULOUS ADMINISTRATION OF GENETICALLY MODIFIED POLYPEPTIDES |
JP2016505613A (ja) | 2013-01-03 | 2016-02-25 | オラムド エルティーディー. | Nafld、脂肪肝、および、その後遺症を処置するための方法および組成物 |
-
2014
- 2014-01-02 JP JP2015551250A patent/JP2016505613A/ja active Pending
- 2014-01-02 CN CN201480003919.4A patent/CN104902921A/zh active Pending
- 2014-01-02 US US14/759,060 patent/US20150335715A1/en not_active Abandoned
- 2014-01-02 EP EP22205280.5A patent/EP4215205A1/en active Pending
- 2014-01-02 EP EP14735143.1A patent/EP2941267B1/en active Active
- 2014-01-02 WO PCT/IL2014/050007 patent/WO2014106846A2/en active Application Filing
- 2014-01-02 CN CN201910287860.0A patent/CN110151979A/zh active Pending
-
2016
- 2016-05-09 HK HK16105268.6A patent/HK1217291A1/zh unknown
-
2018
- 2018-07-11 JP JP2018131875A patent/JP2018197240A/ja active Pending
- 2018-11-19 US US16/195,184 patent/US10967051B2/en active Active
-
2020
- 2020-06-12 JP JP2020102461A patent/JP2020180126A/ja active Pending
-
2021
- 2021-03-19 US US17/206,574 patent/US20220000986A1/en not_active Abandoned
-
2022
- 2022-09-29 JP JP2022156787A patent/JP2023002570A/ja active Pending
-
2023
- 2023-12-21 US US18/392,074 patent/US20240181018A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2014106846A3 (en) | 2015-01-29 |
JP2016505613A (ja) | 2016-02-25 |
JP2020180126A (ja) | 2020-11-05 |
US20150335715A1 (en) | 2015-11-26 |
JP2023002570A (ja) | 2023-01-10 |
WO2014106846A2 (en) | 2014-07-10 |
CN104902921A (zh) | 2015-09-09 |
EP2941267B1 (en) | 2022-11-16 |
US20240181018A1 (en) | 2024-06-06 |
US20190209655A1 (en) | 2019-07-11 |
US20220000986A1 (en) | 2022-01-06 |
JP2018197240A (ja) | 2018-12-13 |
EP2941267A4 (en) | 2016-06-22 |
US10967051B2 (en) | 2021-04-06 |
CN110151979A (zh) | 2019-08-23 |
EP4215205A1 (en) | 2023-07-26 |
EP2941267A2 (en) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273205A (en) | Preparations and methods | |
HK1217291A1 (zh) | 用於治療 、肝性脂肪變性及其後遺症的方法和組合物 | |
HK1218837A1 (zh) | 組合物和方法 | |
HK1218560A1 (zh) | 組成與方法 | |
HK1223625A1 (zh) | 胞苷- -甲酰胺修飾的核苷酸組合物及其相關方法 | |
HK1217608A1 (zh) | 用於消耗品的方法及複合物 | |
GB2533892B (en) | Compositions and methods | |
SG11201507288UA (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
PL3030663T3 (pl) | Kompozycje i sposoby kontroli leptinotarsa | |
ZA201505390B (en) | Compositions and methods for treating pests | |
EP2889350A4 (en) | ADHESIVE COMPOSITION | |
GB201308072D0 (en) | Compositions and methods | |
EP2968165A4 (en) | COMPOSITIONS AND RELATED METHODS FOR RADIOISOTOPE BINDING MICROPARTICLES | |
HK1255453A1 (zh) | 用於治療白血病的方法和組合物 | |
EP3006525A4 (en) | ASPHALT-URETHANE COMPOSITION | |
GB201305414D0 (en) | Method and composition | |
GB201305813D0 (en) | Compositions and methods | |
GB201320409D0 (en) | Prebiotic composition | |
EP3066178A4 (en) | GREASE COMPOSITION | |
HK1217432A1 (zh) | 多核苷酸轉染組合物和方法 | |
EP2964610A4 (en) | VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF | |
EP3016645A4 (en) | PROCEDURE AND COMPOSITIONS FOR DETECTING FROM ABUSE | |
GB201405657D0 (en) | Additive carrying composition | |
GB201322617D0 (en) | Methods and compositions | |
GB201312393D0 (en) | Compositions and Methods |